DE69132710T2 - Verfahren zur Reduzierung von Endotoxin induzierten Effekten - Google Patents

Verfahren zur Reduzierung von Endotoxin induzierten Effekten

Info

Publication number
DE69132710T2
DE69132710T2 DE69132710T DE69132710T DE69132710T2 DE 69132710 T2 DE69132710 T2 DE 69132710T2 DE 69132710 T DE69132710 T DE 69132710T DE 69132710 T DE69132710 T DE 69132710T DE 69132710 T2 DE69132710 T2 DE 69132710T2
Authority
DE
Germany
Prior art keywords
endotoxins
endotoxin
body weight
medicament
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132710T
Other languages
German (de)
English (en)
Other versions
DE69132710D1 (de
Inventor
Christer Grimfors
Ellinor Lampen
Svante Lindgren
Goeran Sandberg
Raymond Wahlen
Bjoern Westberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of DE69132710D1 publication Critical patent/DE69132710D1/de
Publication of DE69132710T2 publication Critical patent/DE69132710T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61L2103/05—

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69132710T 1991-01-09 1991-12-20 Verfahren zur Reduzierung von Endotoxin induzierten Effekten Expired - Fee Related DE69132710T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Publications (2)

Publication Number Publication Date
DE69132710D1 DE69132710D1 (de) 2001-10-04
DE69132710T2 true DE69132710T2 (de) 2002-04-18

Family

ID=20381566

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69132710T Expired - Fee Related DE69132710T2 (de) 1991-01-09 1991-12-20 Verfahren zur Reduzierung von Endotoxin induzierten Effekten
DE69223426T Expired - Fee Related DE69223426T2 (de) 1991-01-09 1991-12-20 Verfahren zur entfernung von endotoxinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69223426T Expired - Fee Related DE69223426T2 (de) 1991-01-09 1991-12-20 Verfahren zur entfernung von endotoxinen

Country Status (11)

Country Link
EP (4) EP0719550B1 (OSRAM)
JP (1) JP3200604B2 (OSRAM)
AT (2) ATE157866T1 (OSRAM)
AU (1) AU9152891A (OSRAM)
DE (2) DE69132710T2 (OSRAM)
DK (2) DK0566644T3 (OSRAM)
ES (2) ES2109338T3 (OSRAM)
GR (1) GR3025573T3 (OSRAM)
PT (1) PT715849E (OSRAM)
SE (1) SE468881B (OSRAM)
WO (1) WO1992011847A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
ES2196053T3 (es) * 1994-01-11 2003-12-16 Stichting Zofia Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
DE69827149T2 (de) * 1997-08-15 2006-03-09 Fairbanks, Carolyn Ann, Rochester Agmatin für die behandlung neuropathischer schmerzen
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1910844B1 (en) 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
EP2043767B1 (en) 2006-07-14 2020-03-25 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation

Also Published As

Publication number Publication date
GR3025573T3 (en) 1998-03-31
ES2163543T3 (es) 2002-02-01
EP0719550B1 (en) 2001-08-29
DK0719550T3 (da) 2001-12-10
SE9100059L (sv) 1992-07-10
DE69223426D1 (de) 1998-01-15
JP3200604B2 (ja) 2001-08-20
ATE204753T1 (de) 2001-09-15
EP0494848A1 (en) 1992-07-15
WO1992011847A1 (en) 1992-07-23
EP0719550A3 (OSRAM) 1996-07-24
ES2109338T3 (es) 1998-01-16
EP0719550A2 (en) 1996-07-03
JPH06504058A (ja) 1994-05-12
EP0715849A1 (en) 1996-06-12
ATE157866T1 (de) 1997-09-15
EP0566644B1 (en) 1997-09-10
DE69223426T2 (de) 1998-03-12
EP0494848B1 (en) 1997-03-26
EP0715849B1 (en) 2001-07-25
DK0566644T3 (da) 1998-04-27
PT715849E (pt) 2002-01-30
SE468881B (sv) 1993-04-05
AU9152891A (en) 1992-08-17
DE69132710D1 (de) 2001-10-04
SE9100059D0 (sv) 1991-01-09
EP0566644A1 (en) 1993-10-27

Similar Documents

Publication Publication Date Title
DE69132710T2 (de) Verfahren zur Reduzierung von Endotoxin induzierten Effekten
DE60115383T2 (de) Hochreine lipopeptide, lipopeptid mizellen, deren herstellung und arzneimittel
EP1153608B1 (de) Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
DE69623354T2 (de) Verwendung von hydrophoben zeolithen, sprize und methode zur entfernung von konservierungsmitteln aus einer polypeptidlösung
DE68904922T2 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
CH640140A5 (de) Verfahren zur herstellung von intravenoes injizierbarem gamma-globulin.
EP1226829B1 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
DD229713A5 (de) Verfahren zur herstellung von gereinigtem htnf
DE3106073A1 (de) Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
DE69626987T2 (de) Pharmaceutische komposition
DE2947646C2 (de) Substanz mit Interferon induzierender Aktivität, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2603122A1 (de) Verfahren zum herstellen von glykoproteinen sowie deren verwendung
DE2823750A1 (de) Verfahren zur trennung von lipoiden der endotoxine von bakterien, insbesondere von bordetella pertussis
EP0395851B1 (de) Glykoproteine aus Avena sativa, Verfahren zu ihrer Herstellung und ihre Verwendung als pharmazeutischer Wirkstoff
CH657989A5 (de) Biologisch aktive substanz, verfahren zur herstellung der substanz, sowie die substanz enthaltende, immunoaktive zusammensetzung.
DE69527205T2 (de) Arzneimittel gegen endotoxinschock und dadurch ausgelöstes multiples organversagen
EP1592439B1 (de) Verfahren zur herstellung einer albuminlösung
DE69233315T2 (de) Pharmazeutische lysin enthaltende polypeptid-zusammensetzungen und verfahren zu deren verwendung
DE2944341A1 (de) Aminosaeuren enthaltendes pharmazeutisches praeparat
DE1617659C3 (de) Interferonbildendes Arzneimittel und dessen Verwendung
DE3027056A1 (de) Pharmazeutischer ansatz zur verwendung als schutz gegen akutes lungenoedem, anaphylaktischen schock u.a. arten von schock sowie hyperfibrinolyse
DE69026275T2 (de) Verfahren zur herstellung von ribonuklease-dimeren
DE3704868C2 (de) Reinigung von rekombinantem Human-Interleukin-1
CH660125A5 (de) Gereinigtes, entgiftetes endotoxin enthaltende zusammensetzung.
DE1617279B2 (de) Verfahren zur Herstellung eines die Aspergillopeptidase ARL 1 enthaltenden Präparates aus Aspergillus oryzae und sie enthaltendes Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee